bimosiamose   Click here for help

GtoPdb Ligand ID: 9049

Synonyms: compound 15e [PMID: 9544210] [4] | TBC 1269 | TBC-1269 | TBC1269
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Bimosiamose is a synthetic pan-selectin antagonist [4] being investigated as a novel anti-inflammatory agent, primarily for controlling allergic respiratory diseases [7,9], but it has also been reported to provide benefit in ischemia/reperfusion injury [1-2,5-6,8]. The primary role of selectin inhibitors appears to be disruption of early events in the migration process (possibly mediated through E-selectin [3]), thereby inhibiting their eventual extravasation from blood to the inflammed tissue.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 14
Hydrogen bond donors 10
Rotatable bonds 19
Topological polar surface area 273.36
Molecular weight 862.34
XLogP 5.95
No. Lipinski's rules broken 4
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OCC1OC(Oc2ccc(cc2c2cccc(c2)CC(=O)O)CCCCCCc2ccc(c(c2)c2cccc(c2)CC(=O)O)OC2OC(CO)C(C(C2O)O)O)C(C(C1O)O)O
Isomeric SMILES OC[C@H]1O[C@H](Oc2ccc(cc2c2cccc(c2)CC(=O)O)CCCCCCc2ccc(c(c2)c2cccc(c2)CC(=O)O)O[C@H]2O[C@H](CO)[C@H]([C@@H]([C@@H]2O)O)O)[C@H]([C@H]([C@@H]1O)O)O
InChI InChI=1S/C46H54O16/c47-23-35-39(53)41(55)43(57)45(61-35)59-33-15-13-25(19-31(33)29-11-5-9-27(17-29)21-37(49)50)7-3-1-2-4-8-26-14-16-34(60-46-44(58)42(56)40(54)36(24-48)62-46)32(20-26)30-12-6-10-28(18-30)22-38(51)52/h5-6,9-20,35-36,39-48,53-58H,1-4,7-8,21-24H2,(H,49,50)(H,51,52)/t35-,36-,39-,40-,41+,42+,43+,44+,45+,46+/m1/s1
InChI Key RYWCQJDEHXJHRI-XJMXIVSISA-N
No information available.
Summary of Clinical Use Click here for help
Bimosiamose has completed Phase 2 clinical trials in patients with chronic obstructive pulmonary disease (COPD; inhaled bimosiamose, NCT01108913 [10]) and psoriasis (topically applied bimosiamose, NCT00823693)
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00823693 Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis Phase 2 Interventional Revotar Biopharmaceuticals AG
NCT01108913 Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Phase 2 Interventional Revotar Biopharmaceuticals AG